Licence agreement for the development of a treatment for Amyotrophic Lateral Sclerosis (ALS)
ILTOO Pharma and the European consortium MIROCALS have just announced the signing of a license agreement for the development of a low-dose Interleukin 2 as a potential treatment for amyotrophic lateral sclerosis (ALS). The AFM-Telethon helped finance this clinical study, which shows an improvement in patient survival.
MIROCALS, a European consortium bringing together research laboratories in the UK, Italy, and Sweden, as well as research support organizations in Ireland, France, and the UK, conducted a study coordinated by Dr Gilbert Bensimon of the Centre Hospitalier Universitaire de Nîmes, to evaluate the effects of low-dose Interleukin 2 in ALS patients. The first clinical results show an improvement in the survival of patients.
The agreement will enable the French biotech ILTOO Pharma to use the data from the MIROCALS study to develop a low-dose interleukin-2 (IL-2LD) treatment for amyotrophic lateral sclerosis (ALS).
ALS is a severe and debilitating degenerative disease that leads to death within 3 to 5 years after diagnosis and which currently has no cure. This agreement for the development of a treatment paves the way to a therapeutic improvement in the management of for people suffering from this terrible disease.
More about MIROCALS study here.